Sports Medicine

, Volume 34, Issue 9, pp 601–627 | Cite as

The Cardiovascular Effects of Chronic Hypoestrogenism in Amenorrhoeic Athletes

A Critical Review
Review Article

Abstract

In premenopausal women, the most severe menstrual dysfunction is amenorrhoea, which is associated with chronic hypoestrogenism. In postmenopausal women, hypoestrogenism is associated with a number of clinical sequelae related to cardiovascular health. A cardioprotective effect of endogenous oestrogen is widely supported, yet recent studies demonstrate a deleterious effect of hormone replacement therapy for cardiovascular health. What remain less clear are the implications of persistently low oestrogen levels in much younger amenorrhoeic athletes. The incidence of amenorrhoea among athletes is much greater than that observed among sedentary women. Recent data in amenorrhoeic athletes demonstrate impaired endothelial function, elevated low- and high-density lipoprotein levels, reduced circulating nitrates and nitrites, and increased susceptibility to lipid peroxidation. Predictive serum markers of cardiovascular health, such as homocysteine and C-reactive protein, have not yet been assessed in amenorrhoeic athletes, but are reportedly elevated in postmenopausal women. The independent and combined effects of chronic hypoestrogenism and exercise, together with subclinical dietary behaviours typically observed in amenorrhoeic athletes, warrants closer examination. Although no longitudinal studies exist, the altered vascular health outcomes reported in amenorrhoeic athletes are suggestive of increased risk for premature cardiovascular disease. Future research should focus on the presentation and progression of these adverse cardiovascular parameters in physically active women and athletes with hypoestrogenism to determine their effects on long-term health.

Keywords

Nitric Oxide Postmenopausal Woman Homocysteine Anorexia Nervosa Hormone Replacement Therapy 

Notes

Acknowledgements

The authors wish to acknowledge the Arthur Thornton Cardiopulmonary Fund. The authors have no conflicts of interest directly relevant to the content of this review.

References

  1. 1.
    Frankovich RJ, Lebrun CM. The athletic woman: menstrual cycle, contraception, and performance. Clin Sports Med 2000; 19(2): 251–71PubMedGoogle Scholar
  2. 2.
    Otis CL, Drinkwater B, Johnson M, et al. American College of Sports Medicine position stand: the female athlete triad. Med Sci Sports Exerc 1997 May; 29(5): i–ixPubMedGoogle Scholar
  3. 3.
    Williams NI, Helmreich DL, Parfitt DB, et al. Evidence for a causal role of low energy availability in the induction of menstrual cycle disturbances during strenuous exercise training. J Clin Endocrinol Metab 2001; 86(11): 5184–93PubMedGoogle Scholar
  4. 4.
    Loucks AB, Verdun M, Heath ME. Low energy availability, not stress of exercise, alters LH pulsatility in exercising women. J Appl Physiol 1998; 84(1): 37–46PubMedGoogle Scholar
  5. 5.
    Loucks AB, Heath EM. Induction of low-T3 syndrome in exercising women occurs at a threshold of energy availability. Am J Physiol 1994; 266: R817–23PubMedGoogle Scholar
  6. 6.
    Wade GN, Schneider JE, Li HY. Control of fertility by metabolic cues. Am J Physiol 1996 Jan; 270(1): E1–19PubMedGoogle Scholar
  7. 7.
    Fruth SJ, Worrell TW. Factors associated with menstrual irregularities and decreased bone mineral density in female athletes. J Orthop Sports Phys Ther 1995 Jul; 22(1): 26–38PubMedGoogle Scholar
  8. 8.
    Drinkwater BL. Exercise and bones: lessons learned from female athletes. Am J Sports Med 1996; 24 (6 Suppl.): S33–5PubMedGoogle Scholar
  9. 9.
    Keen AD, Drinkwater BL. Irreversible bone loss in former amenorrheic athletes. Osteoporos Int 1997; 7(4): 311–5PubMedGoogle Scholar
  10. 10.
    Yeager KK, Agostini R, Nattiv A, et al. The female athlete triad: disordered eating, amenorrhea, osteoporosis. Med Sci Sports Exerc 1993 Jul; 25(7): 775–7PubMedGoogle Scholar
  11. 11.
    Zeni Hoch A, Dempsey RL, Carrera GF, et al. Is there an association between athletic amenorrhea and endothelial cell dysfunction? Med Sci Sports Exerc 2003 Mar; 35(3): 377–83PubMedGoogle Scholar
  12. 12.
    Stevenson J, Crook D, Godsland I. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993; 98: 83–90PubMedGoogle Scholar
  13. 13.
    Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342(12): 836–43PubMedGoogle Scholar
  14. 14.
    Lieberman EH, Gerhard MD, Uehata A, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994 Dec; 121: 936–41PubMedGoogle Scholar
  15. 15.
    Rosenson RS, Tangney CC, Mosca LJ. Hormone replacement therapy improves cardiovascular risk by lowering plasma viscosity in postmenopausal women. Arterioscler Thromb Vasc Biol 1998 Dec; 18(12): 1902–5PubMedGoogle Scholar
  16. 16.
    Moreau KL, Donate AJ, Tanaka H, et al. Basal leg blood flow in healthy women is related to age and hormone replacement therapy status. J Physiol 2003 Feb 15; 547 (Pt 1): 309–16PubMedGoogle Scholar
  17. 17.
    Mijatovic V, Kenemans P, Jakobs C, et al. A randomized controlled study of the effects of 17 beta-estradiol-dydrogester-one on plasma homocysteine in postmenopausal women. Obstet Gynecol 1998 Mar; 91(3): 432–6PubMedGoogle Scholar
  18. 18.
    Yildirir A, Aybar F, Tokgozoglu L, et al. Effects of hormone replacement therapy on plasma homocysteine and C-reactive protein levels. Gynecol Obstet Invest 2002; 53(1): 54–8PubMedGoogle Scholar
  19. 19.
    Yen CH, Hsieh CC, Chou SY, et al. 17 Beta-estradiol inhibits oxidized low density lipoprotein-induced generation of reactive oxygen species in endothelial cells. Life Sci 2001 Dec 14; 70(4): 403–13PubMedGoogle Scholar
  20. 20.
    Wenger NK. Menopausal hormone therapy and cardiovascular protection: state of the data 2003. J Am Med Womens Assoc 2003 Fall; 58(4): 236–9PubMedGoogle Scholar
  21. 21.
    Friday KE, Drinkwater BL, Bruemmer B, et al. Elevated plasma low-density lipoprotein and high-density lipoprotein cholesterol levels in amenorrheic athletes: effects of endogenous hormone status and nutrient intake. J Clin Endocrinol Metab 1993 Dec; 77(6): 1605–9PubMedGoogle Scholar
  22. 22.
    Stacey E, Korkia P, Hukkanen MV, et al. Decreased nitric oxide levels and bone turnover in amenorrheic athletes with spinal osteopenia. J Clin Endocrinol Metab 1998 Sep; 83(9): 3056–61PubMedGoogle Scholar
  23. 23.
    Ayres S, Baer J, Subbiah MT, et al. Exercised-induced increase in lipid peroxidation parameters in amenorrheic female athletes. Fertil Steril 1998 Jan; 69(1): 73–7PubMedGoogle Scholar
  24. 24.
    McArdle WD, Katch FI, Katch VL. Exercise physiology: energy, nutrition, and human performance. 3rd rev. ed. Philidelphia (PA): Lea and Febiger, 1991: 19Google Scholar
  25. 25.
    Bocan TM. Pleiotropic effects of HMG-CoA reductase inhibitors. Curr Opin Investig Drugs 2002 Sep; 3(9): 1312–7PubMedGoogle Scholar
  26. 26.
    Dietschy JM. Dietary fatty acids and the regulation of plasma low density lipoprotein cholesterol concentrations. J Nutr 1998 Feb; 128 (2 Suppl.): 444S–8SPubMedGoogle Scholar
  27. 27.
    NCEP Group. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001 May 16; 285(19): 2486–97Google Scholar
  28. 28.
    Irons BK, Snella KA, McCall K, et al. Update on the management of dyslipidemia. Am J Health Syst Pharm 2002 Sep 1; 59(17): 1615–25PubMedGoogle Scholar
  29. 29.
    Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am 1994; 78: 117–41PubMedGoogle Scholar
  30. 30.
    Chait A, Brunzell JD. Acquired hyperlipidemia (secondary dyslipoproteinemias). Endocrinol Metab Clin North Am 1990; 19: 259–78PubMedGoogle Scholar
  31. 31.
    Ineck BA, Ng TM. Effects of subclinical hypothyroidism and its treatment on serum lipids. Ann Pharmacother 2003 May; 37(5): 725–30PubMedGoogle Scholar
  32. 32.
    Urabe M, Yamamoto T, Kashiwagi T, et al. Effect of estrogen replacement therapy on hepatic triglyceride lipase, lipoprotein lipase and lipids including apolipoprotein E in climacteric and elderly women. Endocr J 1996 Dec; 43(6): 737–42PubMedGoogle Scholar
  33. 33.
    Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas 1990 Nov; 12(4): 321–31PubMedGoogle Scholar
  34. 34.
    Haddock BL, Marshak HP, Mason JJ, et al. The effect of hormone replacement therapy and exercise on cardiovascular disease risk factors in postmenopausal women. Sports Med 2000 Jan; 29(1): 39–49PubMedGoogle Scholar
  35. 35.
    Akahoshi M, Soda M, Nakashima E, et al. Effects of age at menopause on serum cholesterol, body mass index, and blood pressure. Atherosclerosis 2001 May; 156(1): 157–63PubMedGoogle Scholar
  36. 36.
    PEPI Group. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995 Jan 18; 273(3): 199–208Google Scholar
  37. 37.
    Farish E, Spowart K, Barnes JF, et al. Effects of postmenopausal hormone replacement therapy on lipoproteins including lipoprotein (a) and LDL subfractions. Atherosclerosis 1996 Sep 27; 126(1): 77–84PubMedGoogle Scholar
  38. 38.
    Lip GY, Blann AD, Jones AF, et al. Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. Am Heart J 1997 Oct; 134(4): 764–71PubMedGoogle Scholar
  39. 39.
    Jensen J, Riis BJ, Strom V, et al. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol 1987 Jan; 156(1): 66–71PubMedGoogle Scholar
  40. 40.
    Crook D, Cust MP, Gangar KF, et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992 Mar; 166(3): 950–5PubMedGoogle Scholar
  41. 41.
    Hanggi W, Lippuner K, Riesen W, et al. Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein (a): a randomised study. Br J Obstet Gynaecol 1997 Jun; 104(6): 708–17PubMedGoogle Scholar
  42. 42.
    Baer JT. Lipid status in female athletes with low estrogen: applications to cardiovascular risk. Am J Health Studies 1999; 15(1): 29–35Google Scholar
  43. 43.
    Thompson DL, Snead DB, Seip RL, et al. Serum lipid levels and steroidal hormones in women runners with irregular menses. Can J Appl Physiol 1997 Feb; 22(1): 66–77PubMedGoogle Scholar
  44. 44.
    Lamon-Fava S, Fisher EC, Nelson ME, et al. Effect of exercise and menstrual cycle status on plasma lipids, low density lipoprotein particle size, and apolipoproteins. J Clin Endocrinol Metab 1989 Jan; 68(1): 17–21PubMedGoogle Scholar
  45. 45.
    Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260: 641–51PubMedGoogle Scholar
  46. 46.
    Kaiserauer S, Snyder AC, Sleeper M, et al. Nutritional, physiological, and menstrual status of distance runners. Med Sci Sports Exerc 1989 Apr; 21(2): 120–5PubMedGoogle Scholar
  47. 47.
    Marcus R, Cann C, Madvig P, et al. Menstrual function and bone mass in elite women distance runners. Ann Intern Med 1985; 102: 158–63PubMedGoogle Scholar
  48. 48.
    van Baal WM, Smolders RG, van der Mooren MJ, et al. Hormone replacement therapy and plasma homocysteine levels. Obstet Gynecol 1999 Oct; 94(4): 485–91PubMedGoogle Scholar
  49. 49.
    Nova E, Varela P, Lopez-Vidriero I, et al. A one year follow-up study in anorexia nervosa: dietary pattern and anthropometrical evolution. Eur J Clin Nutr 2001; 55: 547–54PubMedGoogle Scholar
  50. 50.
    Sanchez-Muniz FJ, Marcos A, Varela P. Serum lipids and apolipoprotein B values, blood pressure and pulse rate in anorexia nervosa. Eur J Clin Nutr 1991 Jan; 45(1): 33–6PubMedGoogle Scholar
  51. 51.
    Mehler PS, Lezotte D, Eckel R. Lipid levels in anorexia nervosa. Int J Eat Disord 1998 Sep; 24(2): 217–21PubMedGoogle Scholar
  52. 52.
    Feillet F, Feillet-Coudray C, Bard JM, et al. Plasma cholesterol and endogenous cholesterol synthesis during refeeding in anorexia nervosa. Clin Chim Acta 2000 Apr; 294(1–2): 45–56PubMedGoogle Scholar
  53. 53.
    Zak A, Vecka M, Tvrzicka E, et al. Lipid metabolism in anorexia nervosa [in Czech]. Cas Lek Cesk 2003; 142(5): 280–4PubMedGoogle Scholar
  54. 54.
    Nelson ME, Fisher EC, Catsus PD, et al. Diet and bone status in amenorrheic runners. Am J Clin Nutr 1986; 43: 910–6PubMedGoogle Scholar
  55. 55.
    Laughlin GA, Yen SS. Nutritional and endocrine-metabolic aberrations in amenorrheic athletes. J Clin Endocrinol Metab 1996; 81: 4301–9PubMedGoogle Scholar
  56. 56.
    Roeters van Lennep JE, Westerveld HT, Erkelens DW, et al. Risk factors for coronary heart disease: implications of gender. Cardiovasc Res 2002 Feb 15; 53(3): 538–49PubMedGoogle Scholar
  57. 57.
    Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res 1993; 34: 1637–59PubMedGoogle Scholar
  58. 58.
    Dietschy JM. Theoretical considerations of what regulates low-density-lipoprotein and high-density-lipoprotein cholesterol. Am J Clin Nutr 1997; 65: 1581S–9SPubMedGoogle Scholar
  59. 59.
    Liscum L, Munn NJ. Intracellular cholesterol transport. Biochim Biophys Acta 1999 Apr; 1438(1): 19–37PubMedGoogle Scholar
  60. 60.
    Baynes JW. Chemical modification of proteins by lipids in diabetes. Clin Chem Lab Med 2003 Sep; 41(9): 1159–65PubMedGoogle Scholar
  61. 61.
    Stefanick ML, Mackey S, Sheehan M, et al. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med 1998 Jul 2; 339(1): 12–20PubMedGoogle Scholar
  62. 62.
    NIH Consensus Statement. Triglyceride, high density lipoprotein, and coronary heart disease [online]. Available from URL: http://consensus.nih.gov/cons/089/089_intro.htm [Accessed 2003 Oct 1]
  63. 63.
    O’Connell BJ, Genest J. High-density lipoproteins and endothelial function. Circulation 2001; 104: 1978–83PubMedGoogle Scholar
  64. 64.
    Barrett-Connor EL. Testosterone and risk factors for cardiovascular disease in men. Diabetes Metab 1995 Jun; 21(3): 156–61Google Scholar
  65. 65.
    Schwertz DW, Penckofer S. Sex differences and the effects of sex hormones on hemostasis and vascular reactivity. Heart Lung 2001; 30(6): 401–28PubMedGoogle Scholar
  66. 66.
    Mendelsohn ME. Mechanisms of estrogen action in the cardiovascular system. J Steroid Biochem Mol Biol 2000 Nov 30; 74(5): 337–43PubMedGoogle Scholar
  67. 67.
    Karjalainen A, Heikkinen J, Savolainen MJ, et al. Mechanisms regulating LDL metabolism in subjects on peroral and transdermal estrogen replacement therapy. Arterioscler Thromb Vasc Biol 2000 Apr; 20(4): 1101–6PubMedGoogle Scholar
  68. 68.
    Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340(23): 1801–11PubMedGoogle Scholar
  69. 69.
    Muesing RA, Forman MR, Graubard BI, et al. Cyclic changes in lipoprotein and apolipoprotein levels during the menstrual cycle in healthy premenopausal women on a controlled diet. J Clin Endocrinol Metab 1996 Oct; 81(10): 3599–603PubMedGoogle Scholar
  70. 70.
    Chen FP, Lee N, Soong YK, et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cardiovascular risk factors. Menopause 2001 Sep–Oct; 8(5): 347–52PubMedGoogle Scholar
  71. 71.
    West SG, Hinderliter AL, Wells EC, et al. Transdermal estrogen reduces vascular resistance and serum cholesterol in postmenopausal women. Am J Obstet Gynecol 2001 Apr; 184(5): 926–33PubMedGoogle Scholar
  72. 72.
    Kushwaha RS, Lewis DS, Carey KD, et al. Effects of estrogen and progesterone on plasma lipoproteins and experimental atherosclerosis in the baboon (Papio sp.). Arterioscler Thromb 1991 Jan–Feb; 11(1): 23–31PubMedGoogle Scholar
  73. 73.
    Parini P, Angelin B, Rudling M. Importance of estrogen receptors in hepatic LDL receptor regulation. Arterioscler Thromb Vasc Biol 1997; 17: 1800–5PubMedGoogle Scholar
  74. 74.
    Abbey M, Owen A, Suzakawa M, et al. Effects of menopause and hormone replacement therapy on plasma lipids, lipoproteins and LDL-receptor activity. Maturitas 1999; 33: 259–69PubMedGoogle Scholar
  75. 75.
    Homma Y, Homma K, Iizuka S, et al. A case of anorexia nervosa with severe hyperlipoproteinemia. Int J Eat Disord 2002 Jul; 32(1): 121–4PubMedGoogle Scholar
  76. 76.
    Thong FSL, McLean C, Graham TE. Plasma leptin in female athletes: relationship with body fat, reproductive, nutritional, and endocrine factors. J Appl Physiol 2000; 88: 2037–44PubMedGoogle Scholar
  77. 77.
    Loucks AB, Laughlin GA, Mortola JF, et al. Hypothalamic-pituitary-thyroidal function in eumenorrheic and amenorrheic athletes. J Clin Endocrinol Metab 1992 Aug; 75(2): 514–8PubMedGoogle Scholar
  78. 78.
    Laughlin GA, Dominguez CE, Yen SS. Nutritional and endocrine-metabolic aberrations in women with functional hypothalamic amenorrhea. J Clin Endocrinol Metab 1998 Jan; 83(1): 25–32PubMedGoogle Scholar
  79. 79.
    Spieker LE, Sudano I, Hurlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002 Mar 26; 105(12): 1399–402PubMedGoogle Scholar
  80. 80.
    Guetta V, Cannon RO. Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Circulation 1996; 93: 1928–37PubMedGoogle Scholar
  81. 81.
    Lamon-Fava S. High-density lipoproteins: effects of alcohol, estrogen, and phytoestrogens. Nutr Rev 2002 Jan; 60(1): 1–7PubMedGoogle Scholar
  82. 82.
    Segrest JP, Li L, Anantharamaiah GM, et al. Structure and function of apolipoprotein A-I and high-density lipoprotein. Curr Opin Lipidol 2000 Apr; 11(2): 105–15PubMedGoogle Scholar
  83. 83.
    Saku K, Ahmad M, Glas-Greenwalt P, et al. Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb Res 1985 Jul 1; 39(1): 1–8PubMedGoogle Scholar
  84. 84.
    Ramet ME, Ramet M, Lu Q, et al. High-density lipoprotein increases the abundance of eNOS protein in human vascular endothelial cells by increasing its half-life. J Am Coll Cardiol 2003 Jun 18; 41(12): 2288–97PubMedGoogle Scholar
  85. 85.
    Bonnefront-Rousselot D, Therond P, Beaudeux JL, et al. High density lipoprotein (HDL) and the oxidative hypothesis of atherosclerosis. Clin Chem Lab Med 1999; 37: 939–48Google Scholar
  86. 86.
    Bittner V. Lipoprotein abnormalities related to women’s health. Am J Cardiol 2002 Oct 17; 90(8A): 77i–84iPubMedGoogle Scholar
  87. 87.
    Silva PM. Estrogen and the vessel wall: effects on endothelium-dependent stimuli. In: Castro MN, Birkhauser M, Clarkson TB, et al., editors. Menopause and the heart. London: The Parthenon Publishing Group, 1999: 7–14Google Scholar
  88. 88.
    Suda Y, Ohta H, Makita K, et al. Influence of bilateral oophorectomy upon lipid metabolism. Maturitas 1998 Jun 3; 29(2): 147–54PubMedGoogle Scholar
  89. 89.
    Zhang X, Jiao J, Bhavnani BR, et al. Regulation of human apolipoprotein A-1 gene expression by equine estrogens. J Lipid Res 2001; 42: 1789–800PubMedGoogle Scholar
  90. 90.
    Pickar JH, Thorneycroft I, Whitehead M. Effects of hormone replacement therapy on the endometrium and lipid parameters: a review of randomized clinical trials, 1985 to 1995. Am J Obstet Gynecol 1998; 178: 1087–99PubMedGoogle Scholar
  91. 91.
    Perrella J, Berco M, Cecutti A, et al. Potential role of the interaction between equine estrogens, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) in the prevention of coronary heart and neurodegenerative diseases in postmenopausal women. Lipids Health Dis 2003 Jun 20; 2(1): 4PubMedGoogle Scholar
  92. 92.
    Ulloa N, Arteaga E, Bustos P, et al. Sequential estrogen-progestin replacement therapy in healthy postmenopausal women: effects on cholesterol efflux capacity and key proteins regulating high-density lipoprotein levels. Metabolism 2002 Nov; 51(11): 1410–7PubMedGoogle Scholar
  93. 93.
    Podl TR, Zmuda JM, Yurgalevitch SM, et al. Lipoprotein lipase activity and plasma triglyceride clearance are elevated in endurance-trained women. Metabolism 1994 Jul; 43(7): 808–13PubMedGoogle Scholar
  94. 94.
    Williams PT. High-density lipoprotein cholesterol and other risk factors for coronary heart disease in female runners. N Engl J Med 1996; 334(20): 1298–303PubMedGoogle Scholar
  95. 95.
    Zmuda JM, Yurgalevitch SM, Flynn MM, et al. Exercise training has little effect on HDL levels and metabolism in men with initially low HDL cholesterol. Atherosclerosis 1998 Mar; 137(1): 215–21PubMedGoogle Scholar
  96. 96.
    Smorawinska A, Korman E, Rajewski A, et al. Thyroid function and lipid metabolism in patients with anorexia nervosa [in Polish]. Psychiatr Pol 2003 Jan–Feb; 37(1): 39–46PubMedGoogle Scholar
  97. 97.
    Comuzzie AG, Blangero J, Mahaney MC, et al. Triiodothyronine exerts a major pleiotropic effect on reverse cholesterol transport phenotypes. Arterioscler Thromb Vasc Biol 1996 Feb; 16(2): 289–93PubMedGoogle Scholar
  98. 98.
    Harber VJ, Petersen SR, Chilibeck PD. Thyroid hormone concentrations and muscle metabolism in amenorrheic and eumenorrheic athletes. Can J Appl Physiol 1998 Jun; 23(3): 293–306PubMedGoogle Scholar
  99. 99.
    Rapp RJ. Hypertriglyceridemia: a review beyond low-density lipoprotein. Cardiol Rev 2002 May–Jun; 10(3): 163–72PubMedGoogle Scholar
  100. 100.
    Gotto AM. Triglyceride as a risk factor for coronary artery disease. Am J Cardiol 1998; 82: 22Q–5QPubMedGoogle Scholar
  101. 101.
    Fruchart JC, Duriez P. HDL and triglyceride as therapeutic targets. Curr Opin Lipidol 2002 Dec; 13(6): 605–16PubMedGoogle Scholar
  102. 102.
    Rendell M, Hulthen UL, Tornquist C, et al. Relationship between abdominal fat compartments and glucose and lipid metabolism in early postmenopausal women. J Clin Endocrinol Metab 2001; 86: 744–9PubMedGoogle Scholar
  103. 103.
    Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991 Oct 24; 325(17): 1196–204PubMedGoogle Scholar
  104. 104.
    Lobo RA. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 1991; 73: 925–30PubMedGoogle Scholar
  105. 105.
    Erberich LC, Alcantara VM, Picheth G, et al. Hormone replacement therapy in postmenopausal women and its effects on plasma lipid levels. Clin Chem Lab Med 2002 May; 40(5): 446–51PubMedGoogle Scholar
  106. 106.
    Case T, Lemieux S, Kennedy SH, et al. Elevated plasma lipids in patients with binge eating disorders are found only in those who are anorexic. Int J Eat Disord 1999 Mar; 25(2): 187–93PubMedGoogle Scholar
  107. 107.
    Durstine JL, Haskeil WL. Effects of exercise training on plasma lipids and lipoproteins. Exerc Sport Sci Rev 1994; 22: 477–521PubMedGoogle Scholar
  108. 108.
    Brown RC, Cox CM. Effects of high fat versus high carbohydrate diets on plasma lipids and lipoproteins in endurance athletes. Med Sci Sports Exerc 1998 Dec; 30(12): 1677–83PubMedGoogle Scholar
  109. 109.
    Volek JS, Sharman MJ, Gomez AL, et al. An isoenergetic very low carbohydrate diet improves serum HDL cholesterol and triacylglycerol concentrations, the total cholesterol to HDL cholesterol ratio and postprandial pipemic responses compared with a low fat diet in normal weight, normolipidemic women. J Nutr 2003 Sep; 133(9): 2756–61PubMedGoogle Scholar
  110. 110.
    Dekkers JC, van Doornen LJP, Kemper HCG, et al. The role of antioxidant vitamins and enzymes in the prevention of exercise-induced muscle damage. Sports Med 1996; 24: 213–38Google Scholar
  111. 111.
    Sanchez-Quesada JL, Ortega H, Payes-Romero A, et al. LDL from aerobically-trained subjects shows higher resistance to oxidative modification than LDL from sedentary subjects. Atherosclerosis 1997 Jul 25; 132(2): 207–13PubMedGoogle Scholar
  112. 112.
    Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991 Dec; 88(6): 1785–92PubMedGoogle Scholar
  113. 113.
    Tangirala RK, Mol MJ, Steinberg D. Macrophage oxidative modification of low density lipoprotein occurs independently of its binding to the low density lipoprotein receptor. J Lipid Res 1996 Apr; 37(4): 835–43PubMedGoogle Scholar
  114. 114.
    Akova B, Surmen-Gur E, Gur H, et al. Exercise-induced oxidative stress and muscle performance in healthy women: role of vitamin E supplementation and endogenous oestradiol. Eur J Appl Physiol 2001 Jan-Feb; 84(1–2): 141–7PubMedGoogle Scholar
  115. 115.
    Stoks SJ. The role of free radicals in toxicity and disease. J Basic Clin Physiol Pharmacol 1995; 6: 205–28Google Scholar
  116. 116.
    Sikka SC. Relative impact of oxidative stress on male reproductive function. Curr Med Chem 2001 Jun; 8(7): 851–62PubMedGoogle Scholar
  117. 117.
    Urso ML, Clarkson PM. Oxidative stress, exercise, and antioxidant supplementation. Toxicology 2003 Jul 15; 189(1–2): 41–54PubMedGoogle Scholar
  118. 118.
    Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000 Nov 9; 408(6809): 239–47PubMedGoogle Scholar
  119. 119.
    Sen CK. Antioxidants in exercise nutrition. Sports Med 2001; 31(13): 891–908PubMedGoogle Scholar
  120. 120.
    Kanaley JA, Ji LL. Antioxidant enzyme activity during prolonged exercise in amenorrheic and eumenorrheic athletes. Metabolism 1991 Jan; 40(1): 88–92PubMedGoogle Scholar
  121. 121.
    Carmeli E, Coleman R, Reznick AZ. The biochemistry of aging muscle. Exp Gerontol 2002 Apr; 37(4): 477–89PubMedGoogle Scholar
  122. 122.
    Sack MN, Rader DJ, Cannon III RO. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994; 343: 269–70PubMedGoogle Scholar
  123. 123.
    Tranquilli AL, Mazzanti L, Cugini AM, et al. Transdermal estradiol and medroxyprogesterone acetate in hormone replacement therapy are both antioxidants. Gynecol Endocrinol 1995 Jun; 9(2): 137–41PubMedGoogle Scholar
  124. 124.
    Subbiah MT, Kessel B, Agrawal M, et al. Antioxidant potential of specific estrogens on lipid peroxidation. J Clin Endocrinol Metab 1993 Oct; 77(4): 1095–7PubMedGoogle Scholar
  125. 125.
    McManus J, McEneny J, Young IS, et al. The effect of various estrogens and progestogens on the susceptibility of low density lipoproteins to oxidation in vitro. Maturitas 1996; 25: 125–31PubMedGoogle Scholar
  126. 126.
    Shwaery GT, Vita JA, Keaney Jr JF. Antioxidant protection of LDL by physiologic concentrations of estrogens is specific for 17-beta-estradiol. Atherosclerosis 1998 Jun; 138(2): 255–62PubMedGoogle Scholar
  127. 127.
    Bureau I, Laporte F, Favier M, et al. No antioxidant effect of combined HRT on LDL oxidizability and oxidative stress biomarkers in treated post-menopausal women. J Am Coll Nutr 2002 Aug; 21(4): 333–8PubMedGoogle Scholar
  128. 128.
    Lawler JM, Hu Z, Green JS, et al. Combination of estrogen replacement and exercise protects against HDL oxidation in post-menopausal women. Int J Sports Med 2002 Oct; 23(7): 477–83PubMedGoogle Scholar
  129. 129.
    Ozden S, Dildar K, Kadir YH, et al. The effects of hormone replacement therapy on lipid peroxidation and antioxidant status. Maturitas 2001 Apr 20; 38(2): 165–70PubMedGoogle Scholar
  130. 130.
    Ruiz-Larrea MB, Martin C, Martinez R, et al. Antioxidant activities of estrogens against aqueous and lipophilic radicals; differences between phenol and catechol estrogens. Chem Phys Lipids 2000; 105: 179–88PubMedGoogle Scholar
  131. 131.
    Bednarek-Tupikowska G, Bohdanowicz-Pawlak A, Bidzinska B, et al. Serum lipid peroxide levels and erythrocyte glutathione peroxidase and Superoxide dismutase activity in premenopausal and postmenopausal women. Gynecol Endocrinol 2001; 15(4): 298–303PubMedGoogle Scholar
  132. 132.
    Serviddio G, Loverro G, Vicino M, et al. Modulation of endometrial redox balance during the menstrual cycle: relation with sex hormones. J Clin Endocrinol Metab 2002 Jun; 87(6): 2843–8PubMedGoogle Scholar
  133. 133.
    Clarkson PM, Thompson HS. Antioxidants: what role do they play in physical activity and health? Am J Clin Nutr 2000 Aug; 72 (2 Suppl.): 637S–46SPubMedGoogle Scholar
  134. 134.
    Packer L. Oxidants, antioxidant nutrients and the athlete. J Sports Sci 1997 Jun; 15(3): 353–63PubMedGoogle Scholar
  135. 135.
    Clarkson PM. Micronutrients and exercise: anti-oxidants and minerals. J Sports Sci 1995 Summer; 13 Spec. no.: S11–24PubMedGoogle Scholar
  136. 136.
    O’Callaghan YC, Woods JA, O’Brien NM. Oxysterol-induced cell death in U937 and HepG2 cells at reduced and normal serum concentrations. Eur J Nutr 1999 Dec; 38(6): 255–62PubMedGoogle Scholar
  137. 137.
    Palazzetti S, Richard MJ, Favier A, et al. Overloaded training increases exercise-induced oxidative stress and damage. Can J Appl Physiol 2003 Aug; 28(4): 588–604PubMedGoogle Scholar
  138. 138.
    Sen CK. Oxidants and antioxidants in exercise. J Appl Physiol 1995; 79: 675–86PubMedGoogle Scholar
  139. 139.
    Vasankari T, Lehtonen-Veromaa M, Mottonen T, et al. Reduced mildly oxidized LDL in young female athletes. Atherosclerosis 2000 Aug; 151(2): 399–405PubMedGoogle Scholar
  140. 140.
    Child RB, Wilkinson DM, Fallowfield JL, et al. Elevated serum antioxidant capacity and plasma malondialdehyde concentration in response to a simulated half-marathon run. Med Sci Sports Exerc 1998 Nov; 30(11): 1603–7PubMedGoogle Scholar
  141. 141.
    Mastaloudis A, Leonard SW, Traber MG. Oxidative stress in athletes during extreme endurance exercise. Free Radic Biol Med 2001 Oct 1; 31(7): 911–22PubMedGoogle Scholar
  142. 142.
    Tiidus PM. Radical species in inflammation and overtraining. Can J Physiol Pharmacol 1998; 76: 533–8PubMedGoogle Scholar
  143. 143.
    Lovlin R, Cottle W, Pyke I, et al. Are indices of free radical damage related to exercise intensity. Eur J Appl Physiol Occup Physiol 1987; 56(3): 313–6PubMedGoogle Scholar
  144. 144.
    Ji LL. Antioxidants and oxidative stress in exercise. Proc Soc Exp Biol Med 1999 Dec; 222(3): 283–92PubMedGoogle Scholar
  145. 145.
    Marzatico F, Pansarasa O, Bertorelli L, et al. Blood free radical antioxidant enzymes and lipid peroxides following long-distance and lactacidemic performances in highly trained aerobic and sprint athletes. J Sports Med Phys Fitness 1997 Dec; 37(4): 235–3PubMedGoogle Scholar
  146. 146.
    Štvrtinová V, Ferenèík M, Hulín I, et al. Vascular endothelium as a Connecting operator in the information transfer between the cardiovascular and immune systems [in Slovak]. Bratisl Lek Listy 1998; 99: 5–19PubMedGoogle Scholar
  147. 147.
    Bonetti PO, Barsness GW, Keelan PC, et al. Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol 2003 May 21; 41(10): 1761–8PubMedGoogle Scholar
  148. 148.
    Arnal JF, Bayard F. Vasculoprotective effects of oestrogens. Clin Exp Pharmacol Physiol 2001; 28: 1032–4PubMedGoogle Scholar
  149. 149.
    Kinlay S, Ganz P. Relation between endothelial dysfunction and the acute coronary syndrome: implications for therapy. Am J Cardiol 2000 Oct; 86 (8 Suppl. 2): 10–3Google Scholar
  150. 150.
    Vallance P, Hingorani A. Endothelial nitric oxide in humans in health and disease. Int J Exp Pathol 1999 Dec; 80(6): 291–303PubMedGoogle Scholar
  151. 151.
    Celermajer DS, Dollery C, Burch M, et al. Role of endothelium in the maintenance of low pulmonary vascular tone in normal children. Circulation 1994 May; 89(5): 2041–4PubMedGoogle Scholar
  152. 152.
    Maeda S, Miyauchi T, Kakiyama T, et al. Effects of exercise training of 8 weeks and detraining on plasma levels of endothelium-derived factors, endothelin-1 and nitric oxide, in healthy young humans. Life Sci 2001 Jul 20; 69(9): 1005–16PubMedGoogle Scholar
  153. 153.
    Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002–12PubMedGoogle Scholar
  154. 154.
    Panza JA, Casino PR, Kilcoyne CM, et al. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993 May; 87(5): 1468–74PubMedGoogle Scholar
  155. 155.
    Casino PR, Crescence MK, Quyyumi AA, et al. The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation 1993; 88: 2541–7PubMedGoogle Scholar
  156. 156.
    McVeigh GE, Brennan GM, Johnston GD, et al. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992 Aug; 35(8): 771–6PubMedGoogle Scholar
  157. 157.
    Hutchison S. Smoking as a risk factor for endothelial dysfunction. Can J Cardiol 1998 Jul; 14Suppl. D: 20D–2DPubMedGoogle Scholar
  158. 158.
    Zeiher AM, Drexler H, Wollschlager H, et al. Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991 Nov; 84(5): 1984–92PubMedGoogle Scholar
  159. 159.
    Guetta V, Quyyumi AA, Prasad A, et al. The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women. Circulation 1997; 96: 2795–801PubMedGoogle Scholar
  160. 160.
    Ohmichi M, Kanda Y, Hisamoto K, et al. Rapid changes of flow-mediated dilatation after surgical menopause. Maturitas 2003 Feb 25; 44(2): 125–31PubMedGoogle Scholar
  161. 161.
    Joyner MJ, Tschakovsky ME. Nitric oxide and physiologic vasodilation in human limbs: where do we go from here? Can J Appl Physiol 2003 Jun; 28(3): 475–90PubMedGoogle Scholar
  162. 162.
    Koh KK. Effects of estrogen on the vascular wall: vasomotor function and inflammation. Cardiovasc Res 2002 Sep; 55(4): 714–26PubMedGoogle Scholar
  163. 163.
    Gilligan DM, Badar DM, Panza JA, et al. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994 Aug; 90(2): 786–91PubMedGoogle Scholar
  164. 164.
    Gerhard M, Walsh BW, Tawakol A, et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 1998 Sep 22; 98(12): 1158–63PubMedGoogle Scholar
  165. 165.
    Sorensen KE, Dorup I, Hermann AP, et al. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation 1998 Apr 7; 97(13): 1234–8PubMedGoogle Scholar
  166. 166.
    Rosselli M, Imthurn B, Keller PJ, et al. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17β-estradiol and norethisterone acetate: a two-year follow-up study. Hypertension 1995; 25: 848–53PubMedGoogle Scholar
  167. 167.
    Webb CM, Ghatei MA, McNeill JG, et al. 17 beta-estradiol decreases endothelin-1 levels in the coronary circulation of postmenopausal women with coronary artery disease. Circulation 2000; 102: 1617–22PubMedGoogle Scholar
  168. 168.
    Westendorp ICD, Bots ML, Grobbee DE, et al. Menopausal status and distensibility of the common carotid artery. Arterioscler Thromb 1999; 19: 713–7Google Scholar
  169. 169.
    Arora S, Veves A, Caballaro AE, et al. Estrogen improves endothelial function. J Vasc Surg 1998 Jun; 27(6): 1141–6PubMedGoogle Scholar
  170. 170.
    Mihmanli I, Mihmanli V, Kantarci F, et al. The effect of an acute decrease in serum estrogen concentration on vessel walls: determination with color and pulsed Doppler ultrasound. Arch Gynecol Obstet 2003 Jan; 267(3): 134–8PubMedGoogle Scholar
  171. 171.
    Chester A, Jiang C, Borland J, et al. Oestrogen relaxes human epicardial coronary arteries through non-endothelium dependent mechanisms. Coron Artery Dis 1995; 95(6): 417–22Google Scholar
  172. 172.
    Yang AL, Tsai SJ, Jiang MJ, et al. Chronic exercise increases both inducible and endothelial nitric oxide synthase gene expression in endothelial cells of rat aorta. J Biomed Sci 2002 Mar–Apr; 9(2): 149–55PubMedGoogle Scholar
  173. 173.
    Jungersten L, Edlund A, Petersson AS, et al. Plasma nitrate as an index of nitric oxide formation in man: analyses of kinetics and confounding factors. Clin Physiol 1996; 16: 369–79PubMedGoogle Scholar
  174. 174.
    Rodriguez-Plaza LG, Alfieri AB, Cubeddu LX. Urinary excretion of nitric oxide metabolites in runners, sedentary individuals and patients with coronary artery disease: effects of 42 km marathon, 15 km race and a cardiac rehabilitation program. J Cardiovasc Risk 1997 Oct-Dec; 4(5–6): 367–72PubMedGoogle Scholar
  175. 175.
    Blumel JE, Castelo-Branco C, Leal T, et al. Effects of transdermal estrogens on endothelial function in postmenopausal women with coronary disease. Climacteric 2003 Mar; 6(1): 38–44PubMedGoogle Scholar
  176. 176.
    Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992 Nov; 340(8828): 1111–5PubMedGoogle Scholar
  177. 177.
    Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995 Nov 1; 26(5): 1235–41PubMedGoogle Scholar
  178. 178.
    Hoch AZ, Jurva J, Staton M, et al. Is endothelial dysfunction that is associated with amenorrheic athletes reversible [abstract]? Med Sci Sports Exerc 2003; 35(5): S12Google Scholar
  179. 179.
    Wellman GC, Brayden JE, Nelson MT. A proposed mechanism for the cardioprotective effect of oestrogen in women: enhanced endothelial nitric oxide release decreases coronary artery reactivity. Clin Exp Pharmacol Physiol 1996 Mar; 23(3): 260–6PubMedGoogle Scholar
  180. 180.
    Chen Z, Yuhanna IS, Galcheva-Gargova Z, et al. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 1999 Feb; 103(3): 401–6PubMedGoogle Scholar
  181. 181.
    Haynes MP, Russell KS, Bender JR. Molecular mechanisms of estrogen actions on the vasculature. J Nucl Cardiol 2000 Sep-Oct; 7(5): 500–8PubMedGoogle Scholar
  182. 182.
    O’Donnell E, Rodgers CD, Goodman J, et al. Endothelial function in hypoestrogenic physically active women [abstract]. Can J Appl Physiol 2003; 28: S88Google Scholar
  183. 183.
    Galetta F, Ferdinando F, Prattichizzo F, et al. Heart rate variability and left ventricular diastolic function in anorexia nervosa. J Adolesc Health 2003; 32: 416–21PubMedGoogle Scholar
  184. 184.
    Clarkson P, Montgomery HE, Mullen MJ, et al. Exercise training enhances endothelial function in young men. J Am Coll Cardiol 1999 Apr; 33(5): 1379–85PubMedGoogle Scholar
  185. 185.
    Kingwell BA, Jennings GL, Dart AM. Exercise and endothelial function. Circulation 2000 Nov 28; 102(22): E179PubMedGoogle Scholar
  186. 186.
    Kingwell BA. Nitric oxide-mediated metabolic regulation during exercise: effects of training in health and cardiovascular disease. FASEB J 2000 Sep; 14(12): 1685–96PubMedGoogle Scholar
  187. 187.
    Maxwell AJ, Schauble E, Bernstein D, et al. Limb blood flow during exercise is dependent on nitric oxide. Circulation 1998 Jul 28; 98(4): 369–74PubMedGoogle Scholar
  188. 188.
    Sader MA, Celermajer DS. Endothelial function, vascular reactivity and gender differences in the cardiovascular system. Cardiovasc Res 2002 Feb 15; 53(3): 597–604PubMedGoogle Scholar
  189. 189.
    Suzuki T, Nakamura Y, Moriya T, et al. Effects of steroid hormones on vascular functions. Microsc Res Tech 2003 Jan 1; 60(1): 76–84PubMedGoogle Scholar
  190. 190.
    Venkov CD, Rankin AB, Vaughan DE. Identification of authentic estrogen receptor in cultured endothelial cells: a potential mechanism for steroid hormone regulation of endothelial function. Circulation 1996 Aug 15; 94(4): 727–33PubMedGoogle Scholar
  191. 191.
    Karas RH, Patterson BL, Mendelsohn ME. Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 1994 May; 89(5): 1943–50PubMedGoogle Scholar
  192. 192.
    Zhu Y, Bian Z, Lu P, et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science 2002 Jan 18; 295(5554): 505–8PubMedGoogle Scholar
  193. 193.
    Alonso D, Radomski MW. The nitric oxide-endothelin-1 connection. Heart Fail Rev 2003 Jan; 8(1): 107–15PubMedGoogle Scholar
  194. 194.
    Taddei S, Virdis A, Ghiadoni L, et al. Vascular effects of endothelin-1 in essential hypertension: relationship with cyclooxygenase-derived endothelium-dependent contracting factors and nitric oxide. J Cardiovasc Pharmacol 2000; 35 (4 Suppl. 2): S37–40PubMedGoogle Scholar
  195. 195.
    Best PJ, Berger PB, Miller VM, et al. The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women. Ann Intern Med 1998; 128(4): 285–8PubMedGoogle Scholar
  196. 196.
    Wingrove CS, Stevenson JC. 17 beta-Oestradiol inhibits stimulated endothelin release in human vascular endothelial cells. Eur J Endocrinol 1997 Aug; 137(2): 205–8PubMedGoogle Scholar
  197. 197.
    Mathew V, Hasdai D, Lerman A. The role of endothelin in coronary atherosclerosis. Mayo Clin Proc 1996; 71: 769–77PubMedGoogle Scholar
  198. 198.
    Anwaar I, Rendell M, Gottsater A, et al. Hormone replacement therapy in healthy postmenopausal women: effects on intraplatelet cyclic guanosine monophosphate, plasma endothelin-1 and neopterin. J Intern Med 2000 Apr; 247(4): 463–70PubMedGoogle Scholar
  199. 199.
    Haenggi W, Bersinger NA, Mueller MD, et al. Decrease of serum endothelin levels with postmenopausal hormone replacement therapy or tibolone. Gynecol Endocrinol 1999 Jun; 13(3): 202–5PubMedGoogle Scholar
  200. 200.
    Jhund PS, Dawson N, Davie AP, et al. Attenuation of endothelin-1 induced vasoconstriction by 17 beta estradiol is not sustained during long-term therapy in postmenopausal women with coronary heart disease. J Am Coll Cardiol 2001 Apr; 37(5): 1367–73PubMedGoogle Scholar
  201. 201.
    Akishita M, Kozaki K, Eto M, et al. Estrogen attenuates endothelin-1 production by bovine endothelial cells via estrogen receptor. Biochem Biophys Res Commun 1998 Oct 9; 251(1): 17–21PubMedGoogle Scholar
  202. 202.
    Dubey RK, Jackson EK, Keller PJ, et al. Estradiol metabolites inhibit endothelin synthesis by an estrogen receptor-independent mechanism. Hypertension 2001 Feb; 37 (2 Pt 2): 640–4PubMedGoogle Scholar
  203. 203.
    Polderman KH, Stehouwer CD, van Kamp GJ, et al. Modulation of plasma endothelin levels by the menstrual cycle. Metabolism 2000 May; 49(5): 648–50PubMedGoogle Scholar
  204. 204.
    Maeda S, Tanabe T, Miyauchi T, et al. Aerobic exercise training reduces plasma endothelin-1 concentration in older women. J Appl Physiol 2003 Jul; 95(1): 336–41PubMedGoogle Scholar
  205. 205.
    Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996 Mar; 27(3): 517–27PubMedGoogle Scholar
  206. 206.
    Dimitrova KR, DeGroot K, Myers AK, et al. Estrogen and homocysteine. Cardiovasc Res 2002 Feb 15; 53(3): 577–88PubMedGoogle Scholar
  207. 207.
    Ozkan Y, Ozkan E, Simsek B. Plasma total homocysteine and cysteine levels as cardiovascular risk factors in coronary heart disease. Int J Cardiol 2002 Mar; 82(3): 269–77PubMedGoogle Scholar
  208. 208.
    Warren CJ. Emergent cardiovascular risk factor: homocysteine. Prog Cardiovasc Nurs 2002 Winter; 17(1): 35–41PubMedGoogle Scholar
  209. 209.
    Verhoef P, Kok FJ, Kruyssen DA, et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 989–95PubMedGoogle Scholar
  210. 210.
    Dimitrova KR, DeGroot KW, Suyderhoud JP, et al. 17-beta estradiol preserves endothelial cell viability in an in vitro model of homocysteine-induced oxidative stress. J Cardiovasc Pharmacol 2002 Mar; 39(3): 347–53PubMedGoogle Scholar
  211. 211.
    Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A 1994 Jul 5; 91(14): 6369–73PubMedGoogle Scholar
  212. 212.
    Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993; 91: 2873–9PubMedGoogle Scholar
  213. 213.
    Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease: enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17: 2074–81PubMedGoogle Scholar
  214. 214.
    McCully KS. Chemical pathology of homocysteine: I. Atherogenesis. Ann Clin Lab Sci 1993 Nov–Dec; 23(6): 477–93PubMedGoogle Scholar
  215. 215.
    Kang SS, Wong PWK, Norusis M. Homocysteinemia due to folate deficiency. Metabolism 1987; 36: 458–62PubMedGoogle Scholar
  216. 216.
    Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997 Jul; 337(4): 230–6PubMedGoogle Scholar
  217. 217.
    Wouters MG, Moorrees MT, van der Mooren MJ, et al. Plasma homocysteine and menopausal status. Eur J Clin Invest 1995 Nov; 25(11): 801–5PubMedGoogle Scholar
  218. 218.
    Walker MC, Smith GN, Perkins SL, et al. Changes in homocysteine levels during normal pregnancy. Am J Obstet Gynecol 1999 Mar; 180 (3 Pt 1): 660–4PubMedGoogle Scholar
  219. 219.
    Boers GHJ, Smals AGH, Trijbels JMF, et al. Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years. J Clin Invest 1983; 72: 1971–6PubMedGoogle Scholar
  220. 220.
    Venkatraman JT, Pendergast DR. Effect of dietary intake on immune function in athletes. Sports Med 2002; 32(5): 323–37PubMedGoogle Scholar
  221. 221.
    Hawley JA, Dennis SC, Lindsay FH, et al. Nutritional practices of athletes: are they sub-optimal? J Sports Sci 1995 Summer; 13 Spec. no.: S75–81PubMedGoogle Scholar
  222. 222.
    Kopp-Woodroffe SA, Manore MM, Dueck CA, et al. Energy and nutrient status of amenorrheic athletes participating in a diet and exercise training intervention program. Int J Sports Nutr 1999; 9: 70–88Google Scholar
  223. 223.
    Ubbink JB, Vermaak WJH, van der Merwe A, et al. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994; 124: 1927–33PubMedGoogle Scholar
  224. 224.
    Moyano D, Vilaseca MA, Artuch R, et al. Plasma total-homo-cysteine in anorexia nervosa. Eur J Clin Nutr 1998 Mar; 52(3): 172–5PubMedGoogle Scholar
  225. 225.
    Tallova J, Tomandl J, Bicikova M, et al. Changes of plasma total homocysteine levels during the menstrual cycle. Eur J Clin Invest 1999 Dec; 29(12): 1041–4PubMedGoogle Scholar
  226. 226.
    Upchurch Jr GR, Welch GN, Fabian AJ, et al. Homocyst (e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997; 272: 17012–7PubMedGoogle Scholar
  227. 227.
    Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999 Nov; 138 (5 Pt 2): S419–20PubMedGoogle Scholar
  228. 228.
    Silvestri A, Gebara O, Vitale C, et al. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation 2003 Jul 1; 107(25): 3165–9PubMedGoogle Scholar
  229. 229.
    Culley FJ, Bodman-Smith KB, Ferguson MA, et al. C-reactive protein binds to phosphorylated carbohydrates. Glycobiology 2000 Jan; 10(1): 59–65PubMedGoogle Scholar
  230. 230.
    Koenig W, Sund M, Frohlich M, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999 Jan; 99(2): 237–42PubMedGoogle Scholar
  231. 231.
    Blake GJ, Ridker PM. C-reactive protein, subclinical atherosclerosis, and risk of cardiovascular events. Arterioscler Thromb Vasc Biol 2002 Oct 1; 22(10): 1512–3PubMedGoogle Scholar
  232. 232.
    Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98(8): 731–3PubMedGoogle Scholar
  233. 233.
    Pepys MB. The acute phase response and C-reactive protein. In: Weatherall DJ, Ledingham JGC, Warrell DA, editors. Oxford textbook of medicine. New York: Oxford University Press, 1996: 1527–33Google Scholar
  234. 234.
    Heilbronn LK, Noakes M, Clifton PM. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol 2001 Jun; 21(6): 968–70PubMedGoogle Scholar
  235. 235.
    Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003 Jun; 111(12): 1805–11PubMedGoogle Scholar
  236. 236.
    Fallon KE, Fallon SK, Boston T. The acute phase response and exercise: court and field sports. Br J Sports Med 2001 Jun; 35(3): 170–3PubMedGoogle Scholar
  237. 237.
    Rosenson RS, Koenig W. Utility of inflammatory markers in the management of coronary artery disease. Am J Cardiol 2003 Jul 3; 92(1A): 10i–8iPubMedGoogle Scholar
  238. 238.
    Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) study. Circulation 1999; 100: 717–22PubMedGoogle Scholar
  239. 239.
    Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999 Aug; 100(7): 713–6PubMedGoogle Scholar
  240. 240.
    Oger E, Alhenc-Gelas M, Plu-Bureau G, et al. Association of circulating cellular adhesion molecules with menopausal status and hormone replacement therapy: time-dependent change in transdermal, but not oral estrogen users. Thromb Res 2001 Jan; 101(2): 35–43PubMedGoogle Scholar
  241. 241.
    Mattusch F, Dufaux B, Heine O, et al. Reduction of the plasma concentration of C-reactive protein following nine months of endurance training. Int J Sports Med 2000 Jan; 21(1): 21–4PubMedGoogle Scholar
  242. 242.
    Dufaux B, Order U, Geyer H, et al. C-reactive protein serum concentrations in well-trained athletes. Int J Sports Med 1984 Apr; 5(2): 102–6PubMedGoogle Scholar
  243. 243.
    Akimoto T, Furudate M, Saitoh M, et al. Increased plasma concentrations of intercellular adhesion molecule-1 after strenuous exercise associated with muscle damage. Eur J Appl Physiol 2002 Jan; 86(3): 185–90PubMedGoogle Scholar
  244. 244.
    Radomski M. Sports injuries [online]. Available from URL: http://www.canultimate.com/articles/Radomski.html [Accessed 2003 Aug 21]
  245. 245.
    MacIntyre DL, Reid WD, McKenzie DC. Delayed muscle soreness: the inflammatory response to muscle injury and its clinical implications. Sports Med 1995 Jul; 20(1): 24–40PubMedGoogle Scholar
  246. 246.
    Tiidus PM. Estrogen and gender effects on muscle damage, inflammation, and oxidative stress. Can J Appl Physiol 2000 Aug; 25(4): 274–87PubMedGoogle Scholar
  247. 247.
    Loucks AB, Horvath SM. Athletic amenorrhea: a review. Med Sci Sports Exerc 1985 Feb; 17(1): 56–72PubMedGoogle Scholar
  248. 248.
    Taubes G. Cardiovascular disease: does inflammation cut to the heart of the matter? Science 2002; 296: 242–5PubMedGoogle Scholar
  249. 249.
    Yudkin JS, Stehouwer CDA, Emeis JJ, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972–8PubMedGoogle Scholar
  250. 250.
    Sites CK, Toth MJ, Cushman M, et al. Menopause-related differences in inflammation markers and their relationship to body fat distribution and insulin-stimulated glucose disposal. Fertil Steril 2002 Jan; 77(1): 128–35PubMedGoogle Scholar
  251. 251.
    Bermudez EA, Rifai N, Buring J, et al. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 2002 Oct 1; 22(10): 1668–73PubMedGoogle Scholar
  252. 252.
    Robson P. Elucidating the unexplained underperformance syndrome in endurance athletes: the interleukin-6 hypothesis. Sports Med 2003; 33(10): 771–81PubMedGoogle Scholar
  253. 253.
    Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 2003 Jun; 88(6): 2470–8PubMedGoogle Scholar
  254. 254.
    Nova E, Samartin S, Gomez S, et al. The adaptive response of the immune system to the particular malnutrition of eating disorders. Eur J Clin Nutr 2002 Aug; 56Suppl. 3: S34–7PubMedGoogle Scholar
  255. 255.
    Montera A, Lopez-Varela S, Nova E, et al. The implication of the binomial nutrition-immunity on sportswomen’s health. Eur J Clin Nutr 2002 Aug; 56 (3 Suppl.): S38–41Google Scholar
  256. 256.
    Beckvid Henriksson G, Schnell C, Linden Hirschberg A. Women endurance runners with menstrual dysfunction have prolonged interruption of training due to injury. Gynecol Obstet Invest 2000; 49(1): 41–6PubMedGoogle Scholar
  257. 257.
    Pedersen BK, Steensberg A, Fischer C, et al. Searching for the exercise factor: is IL-6 a candidate? J Muscle Res Cell Motil 2003; 24(2–3): 113–9PubMedGoogle Scholar
  258. 258.
    De Souza MJ, Maguire MS, Maresh CM, et al. Adrenal activation and the prolactin response to exercise in eumenorrheic and amenorrheic runners. J Appl Physiol 1991 Jun; 70(6): 2378–87PubMedGoogle Scholar
  259. 259.
    Rome ES. Epidemiology of eating disorders. Obstet Gynecol Clin North Am 2003; 30(2): 353–77PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Women’s Exercise and Bone Health Laboratory, Faculty of Physical Education and HealthUniversity of Toronto, OntarioTorontoCanada

Personalised recommendations